COMPARISON
tDCS and TMS are not two versions of the same technology. Here is how they actually differ — mechanism, evidence, cost, and who each one is really built for.
Loading…
Continue Reading
Related articles from the knowledge base
THE MECHANISM
What Is tDCS? Transcranial Direct Current Stimulation Guide (2026)
10 min read
THE SCIENCE
We Reviewed 25 Peer-Reviewed Studies So You Don't Have To. Here's What the Science Actually Says About tDCS.
15 min read
COMPARISON
Three Neurostimulation Devices. Three Completely Different Jobs.
12 min read
FREQUENTLY ASKED
tDCS uses a low-level electrical current through scalp electrodes to gently shift neuron excitability in a targeted brain region. TMS uses pulsed magnetic fields to induce stronger electrical currents inside the brain that can directly trigger neuron firing. tDCS is subtle and portable; TMS is more powerful and requires clinical equipment.
TMS currently has the strongest and most consistent clinical evidence base for depression, particularly for treatment-resistant cases, where multiple antidepressant trials have failed. tDCS received its first US FDA approval for depression in December 2025, with its pivotal trial showing a 44.9% remission rate at ten weeks versus 21.8% under sham. For mild to moderate depression, tDCS is a viable option; for treatment-resistant depression, TMS has a more established track record.
Yes. As of December 2025, the FDA approved the first prescription home-use tDCS device, the Flow Neuroscience FL-100, for moderate to severe major depressive disorder. It is used at home under remote clinical supervision via an app and requires a doctor's prescription. Consumer wellness tDCS devices are also available without a prescription for non-medical uses.
Neither is typically painful. tDCS users commonly notice a mild tingling or itching sensation under the electrodes, most noticeable in the first minute. TMS produces a repetitive tapping sensation on the scalp and a loud clicking sound from the coil. Some people find the early sessions of TMS uncomfortable; this usually decreases as treatment progresses. Both are generally well-tolerated with low dropout rates in clinical trials.
At standard parameters (≤2 mA, 20–30 minute sessions), tDCS has a well-documented safety profile in research. Reported side effects are mild: tingling, minor skin redness, and occasional headaches. Skin burns are rare and typically linked to improper electrode maintenance. People with epilepsy, recent head injury, or metal implants near the skull should consult a physician before use.
Many major US insurers cover TMS for treatment-resistant depression when patients meet defined clinical criteria, typically failure to respond to at least two antidepressant medications. Coverage has expanded significantly over the past several years. Coverage terms vary by plan; always verify directly with your insurer and the treating clinic before starting.
A standard TMS course involves daily sessions (five days per week) for four to six weeks, typically 20 to 36 sessions in total. Session duration ranges from about 3 minutes (theta burst stimulation) to 40 minutes (older rTMS protocols). Accelerated protocols compress the full course into five days using multiple sessions per day, but these remain available at a limited number of specialist centres.
Research results are mixed but directionally positive under the right conditions. Studies applying anodal tDCS to the left prefrontal cortex have shown improvements in working memory speed, attention, and executive function in healthy adults, particularly when stimulation is delivered concurrently with active cognitive tasks. The effects are more variable in passive-use paradigms. Interventions of ten or more sessions at 2 mA show the most consistent results in the research literature.
In the US, TMS is FDA-cleared for major depressive disorder, obsessive-compulsive disorder (OCD), anxious depression, smoking cessation (using a deep TMS protocol), and, as of November 2025, adolescent MDD in patients aged 15 to 21. Research is ongoing for PTSD, generalized anxiety disorder, chronic pain, and various neurological conditions.
The FDA-approved tDCS device for depression explicitly covers use as both monotherapy and as an adjunct to antidepressants or psychotherapy. TMS is also frequently used alongside medication. Combining brain stimulation with ongoing therapy is generally viewed positively in the literature. Stimulation may enhance the neuroplasticity created during therapeutic engagement. Always inform your prescribing clinician about all current treatments.
THE INSTRUMENT
Sychedelic combines everything described in this article into one 20-minute protocol.